SILEXION THERAPEUTICS CORP Earnings Per Share (Basic)
SILEXION THERAPEUTICS CORP (SLXN) reported Earnings Per Share (Basic) of $5.17 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP earnings per share, basic for the quarter ending 2026-06-30 was $5.17, a 88.03% decline year-over-year.
- SILEXION THERAPEUTICS CORP earnings per share, basic for the quarter ending 2026-03-31 was $8.46, a 77.96% decline year-over-year.
- SILEXION THERAPEUTICS CORP earnings per share, basic for the quarter ending 2025-12-31 was -$2.69.
- SILEXION THERAPEUTICS CORP earnings per share, basic for the quarter ending 2025-09-30 was $2.88, a 98.95% decline year-over-year.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.17 10-Q · filed 2026-08-14 | $12.41 10-Q · filed 2026-08-14 | ||||||
| 2026-03-31 | $8.46 S-1/A · filed 2026-08-10 | $0.85 10-Q · filed 2026-05-15 | ||||||
| 2025-12-31 | -$2.69 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$30.26 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$67.96 derived: net income ÷ weighted average shares · filed 2026-08-14 | $89.61 S-1/A · filed 2026-08-10 | $8.96 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $2.88 10-Q · filed 2025-11-12 | $9.68 derived: net income ÷ weighted average shares · filed 2026-08-14 | $10.36 10-Q · filed 2025-11-12 | $30.98 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-06-30 | $43.19 10-Q · filed 2026-08-14 | $4.32 10-Q · filed 2025-08-12 | $82.12 10-Q · filed 2026-08-14 | $8.21 10-Q · filed 2025-08-12 | $292.56 derived: net income ÷ weighted average shares · filed 2026-08-14 | $682.17 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2025-03-31 | $38.39 S-1/A · filed 2026-08-10 | $0.26 10-Q · filed 2025-05-13 | $2036.85 derived: net income ÷ weighted average shares · filed 2026-08-10 | $986.43 derived: net income ÷ weighted average shares · filed 2026-08-10 | $1243.11 derived: net income ÷ weighted average shares · filed 2026-08-10 | |||
| 2024-12-31 | -$41.82 derived: net income ÷ weighted average shares · filed 2026-08-10 | $18965.13 derived: net income ÷ weighted average shares · filed 2026-08-10 | $5093.51 derived: net income ÷ weighted average shares · filed 2026-08-10 | $3955.11 S-1/A · filed 2026-08-10 | $26.36 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $274.25 10-Q · filed 2025-11-12 | $2.03 10-Q · filed 2024-11-14 | $526.03 derived: net income ÷ weighted average shares · filed 2025-11-12 | $754.85 10-Q · filed 2025-11-12 | $5.60 10-Q · filed 2024-11-14 | -$23.26 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||
| 2024-06-30 | $197.80 10-Q · filed 2025-08-12 | $5.87 10-Q · filed 2024-08-29 | $381.09 10-Q · filed 2025-08-12 | $11.31 10-Q · filed 2024-08-29 | -$4.78 derived: net income ÷ weighted average shares · filed 2025-08-20 | -$11.51 derived: net income ÷ weighted average shares · filed 2025-08-20 | ||
| 2024-03-31 | $12.29 10-Q · filed 2025-05-13 | -$2.16 derived: net income ÷ weighted average shares · filed 2025-08-20 | -$6.24 derived: net income ÷ weighted average shares · filed 2025-08-20 | -$13.71 derived: net income ÷ weighted average shares · filed 2025-08-20 | ||||
| 2023-12-31 | -$0.58 derived: net income ÷ weighted average shares · filed 2025-08-20 | -$2.54 derived: net income ÷ weighted average shares · filed 2025-08-20 | -$7.23 derived: net income ÷ weighted average shares · filed 2025-08-20 | $659.55 8-K · filed 2025-08-20 | $44.23 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $0.78 10-Q · filed 2024-11-14 | $3.88 derived: net income ÷ weighted average shares · filed 2024-11-14 | $3.20 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $6.54 10-Q · filed 2024-08-29 | $9.61 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |